Catalyst Pharmaceuticals (CPRX +5.4%) is up on below-average volume on the heels of its preliminary 2019 results and 2020 guidance.
Firdapse (amifampridine): Q4 2019 sales should be ~$30M. The total for the year should be ~$102M.
Quick assets at year-end should be ~$95M with no funded debt.
2020 outlook: Firdapse revenue for LEMS should be $135M – 155M. R&D and SG&A expenses should be ~$65M.
Topline data from a Phase 3 clinical trial evaluating Firdapse in patients with MuSK antibody-positive myasthenia gravis should be available in H1. If all goes well, the company expects to file a supplemental marketing application in the U.S. by year-end.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.